Great results on a bispecific gylcopeptide (bsGP) from National Center for Nanoscience and Technology in anticancer therapy. bsGP simultaneously targets CD206 on tumor-associated macrophages (TAMs) and CXCR4 on tumor cells, repolarizing protumoral M2-like TAMs to antitumor M1-like that mediated cytotoxicity and T cell recruitment. bsGP reduces the matrix microenvironment barrier, increasing the spatially redirected CD8+ T cells to tumor cells. The authors envision that bis-targeting CD206 and CXCR4 may pave the way to inhibit tumor metastasis and recurrence.
